Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.
Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.
复制标题
DOI：
10.1016/j.str.2021.05.014
复制
发表时间：
2021-07-01
期刊：
影响因子：
--
通讯作者：
Shapiro L
中科院分区：
文献类型：
--
作者：
Cerutti G;Rapp M;Guo Y;Bahna F;Bimela J;Reddem ER;Yu J;Wang P;Liu L;Huang Y;Ho DD;Kwong PD;Sheng Z;Shapiro L
分别来自英国和南非的新出现的 SARS-CoV-2 毒株 B.1.1.7 和 B.1.351 显示出针对原始野生型病毒的单克隆抗体和恢复期或疫苗接种者血清的中和作用降低，因此受到临床关注。然而，针对刺突受体结合域 (RBD) 的两种抗体 1-57 和 2-7 的中和效力并未受到这些新兴菌株的影响。在这里，我们报告了 1-57 和 2-7 与刺突复合物的冷冻电镜结构，揭示了这些抗体中的每一种都利用独特的机制来绕过或适应 RBD 突变。值得注意的是，每种抗体都代表了一种免疫反应，其识别能力与常见抗体类别不同。此外，1-57 和 2-7 识别的许多表位残基处于 ACE2 结合和中和抗体逃逸的进化压力热点之外。我们建议使用针对不太常见表位的抗体（例如 1-57 和 2-7）进行治疗，可以改善单克隆抗体逃逸的问题。切鲁蒂等人。报告了与 SARS-CoV-2 刺突结合的两种有效中和抗体 1-57 和 2-7 的结构特征。冷冻电镜结构阐明了适应 B.1.1.7 和 B.1.351 变体中观察到的 RBD 突变的不同机制。这两种抗体都代表低频免疫反应，建议将它们用作治疗剂。
Emerging SARS-CoV-2 strains, B.1.1.7 and B.1.351, from the UK and South Africa, respectively, show decreased neutralization by monoclonal antibodies and convalescent or vaccinee sera raised against the original wild-type virus, and are thus of clinical concern. However, the neutralization potency of two antibodies, 1–57 and 2–7, which target the receptor-binding domain (RBD) of the spike, was unaffected by these emerging strains. Here, we report cryo-EM structures of 1–57 and 2–7 in complex with spike, revealing each of these antibodies to utilize a distinct mechanism to bypass or accommodate RBD mutations. Notably, each antibody represented an immune response with recognition distinct from those of frequent antibody classes. Moreover, many epitope residues recognized by 1–57 and 2–7 were outside hotspots of evolutionary pressure for ACE2 binding and neutralizing antibody escape. We suggest the therapeutic use of antibodies, such as 1–57 and 2–7, which target less prevalent epitopes, could ameliorate issues of monoclonal antibody escape. Cerutti et al. report the structural characterization of two potent neutralizing antibodies, 1–57 and 2–7, bound to the SARS-CoV-2 spike. The cryo-EM structures elucidate distinct mechanisms to accommodate the RBD mutations observed in the B.1.1.7 and B.1.351 variants. Both antibodies represent low-frequency immune responses and their use as therapeutics is suggested.
登录
查看更多内容
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
影响因子：
48
作者：
Barad BA;Echols N;Wang RY;Cheng Y;DiMaio F;Adams PD;Fraser JS
通讯作者：
Fraser JS
影响因子：
14.9
作者：
Dunbar J;Krawczyk K;Leem J;Marks C;Nowak J;Regep C;Georges G;Kelm S;Popovic B;Deane CM
通讯作者：
Deane CM
DOI：
10.1107/s0907444904019158
发表时间：
2004-12-01
影响因子：
2.2
作者：
Emsley, P;Cowtan, K
通讯作者：
Cowtan, K
影响因子：
8.8
作者：
Rapp M;Guo Y;Reddem ER;Yu J;Liu L;Wang P;Cerutti G;Katsamba P;Bimela JS;Bahna FA;Mannepalli SM;Zhang B;Kwong PD;Huang Y;Ho DD;Shapiro L;Sheng Z
通讯作者：
Sheng Z